Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fusion Pharmaceuticals Inc. (FUSN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.40-0.09 (-1.20%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.49
Open8.01
Bid7.20 x 800
Ask7.54 x 800
Day's Range7.36 - 8.02
52 Week Range6.61 - 13.89
Volume16,125
Avg. Volume39,951
Market Cap318.121M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.20
  • CNW Group

    Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer

    Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Mohit Rawat as President and Chief Business Officer. Mr. Rawat brings to Fusion more than 15 years of experience in the biopharmaceutical industry, with expertise in corporate strategy, business development and commercial execution, including product development, launch planning and commercialization.

  • PR Newswire

    Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

    Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 2:40pm ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

  • PR Newswire

    Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development

    Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development.

Advertisement
Advertisement